What was West Pharmaceutical's revenue in Q2 2026?

Revenue was $872.3 million, up 13.8% year over year.

Did West Pharmaceutical's EPS beat estimates?

Yes, non-GAAP EPS of $2.37 beat consensus by 13.9%.

What is the revenue guidance for next quarter?

The company guided revenue of $827.5 million at the midpoint, 0.8% above analyst estimates.

What drove the growth this quarter?

Growth was driven by strong demand for high-value delivery components used in biologic drugs.

Did the company raise its annual guidance?

Yes, the company raised its full-year guidance, but did not provide specific details.

West Pharmaceutical Q2 2026 Beats Estimates on Biologics Strength

West Pharmaceutical Services reported Q2 2026 results above market expectations, with revenue up 13.8% YoY to $872.3 million and non-GAAP EPS of $2.37, beating consensus by 13.9%, while raising future guidance.

West Pharmaceutical Services (NYSE:WST) reported Q2 2026 results exceeding market expectations, with revenue of $872.3 million, up 13.8% year over year, driven by strong demand for biologics and high-value components. Non-GAAP earnings per share came in at $2.37, 13.9% above analyst consensus estimates.

Key Financial Results

Metric	Q2 2026	vs. Estimates
Revenue	$872.3M	+0.8% above
Revenue Growth (YoY)	13.8%	-
Non-GAAP EPS	$2.37	+13.9% above

Highlights from the Release

The company attributed its strong performance to increased demand for high-value delivery components used in biologic drugs, along with improved operational efficiency. West noted positive momentum across all key markets.

Future Guidance

West guided next quarter's revenue at $827.5 million at the midpoint, 0.8% above analyst estimates. The company also raised its full-year guidance, though no specific details were provided.

Impact on the Stock

The beat-and-raise is expected to bolster investor confidence in WST, particularly given its exposure to the high-growth biologics sector.

What This Means for Investors

The results reaffirm the strength of West Pharmaceutical's business model tied to advanced biologic drugs. Investors should monitor the company's ability to sustain growth amid competition and economic headwinds.